Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY14 | Q15391 | 3/20 | 0.47 |
| ▸ | SLC28A1 | O00337 | 1/20 | 0.44 |
| ▸ | SLC28A2 | O43868 | 1/20 | 0.44 |
| ▸ | SLC29A1 | Q99808 | 1/20 | 0.44 |
| ▸ | SLC28A3 | Q9HAS3 | 1/20 | 0.44 |
| ▸ | P2RY2 | P41231 | 10/20 | 0.43 |
| ▸ | P2RY6 | Q15077 | 9/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | P2RY4 | P51582 | 3/20 | 0.42 |
| ▸ | P2RY12 | Q9H244 | 2/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6361053 | 0.97 | P2RY14 (0.47) | P2RY14SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL707273 | 0.90 | NT5E (0.41) | P2RY14SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL707274 | 0.88 | P2RY14 (0.40) | P2RY14SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL6360276 | 0.83 | DUT (0.38) | P2RY14P2RY2P2RY6NT5EP2RY4 | |
| SCHEMBL6360279 | 0.81 | DUT (0.38) | P2RY14P2RY2P2RY6NT5EP2RY4 | |
| SCHEMBL705298 | 0.79 | TDP1 (0.39) | P2RY14P2RY2P2RY6NT5EP2RY4 | |
| SCHEMBL4668184 | 0.79 | SLC28A1 (0.50) | P2RY14SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL12434636 | 0.78 | TYMP (0.62) | P2RY14SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL918583 | 0.78 | TYMP (0.62) | P2RY14SLC28A1SLC28A2SLC29A1SLC28A3 | |
| SCHEMBL918582 | 0.78 | TYMP (0.62) | P2RY14SLC28A1SLC28A2SLC29A1SLC28A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6858591-B2 | Antibiotic AA 896 analogs | WYETH HOLDINGS CORPORATION (US) | 2005-02-22 | — | — | US | disclosed |
| US-20030087874-A1 | 2-amino-3-hydroxy-3-uridyl-propanoic acid ester derivatives | AMERICAN CYANAMID COMPANY | 2003-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087874-A1 | 2-amino-3-hydroxy-3-uridyl-propanoic acid ester derivatives | UMPS, METTL3, FPR3 | P2RY14 760/4885SLC28A1 563/4885SLC28A2 785/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.